TEPMETKO tepotinib

Drug Class

MET kinase inhibitor

Mechanism

Inhibits MET receptor tyrosine kinase phosphorylation, preventing downstream signaling that drives tumor growth and angiogenesis.

Approved Indication

Metastatic non-small cell lung cancer harboring MET exon 14 skipping alterations, per its FDA approval.

What This Means For Patients

Tepmetko is a targeted oral therapy for patients with advanced non-small cell lung cancer driven by MET exon 14 skipping alterations. It works by blocking aberrant MET pathway signaling, and patients can access it through the Hainan Boao Lecheng special import scheme.

Regulatory Approvals

• FDA — approved (2021) — label

Pivotal Clinical Evidence

• VISION — Paik et al., N Engl J Med 2020 (NCT02864992) — DOI

Sources

• https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-tepotinib-metastatic-non-small-cell-lung-cancer
• https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214096s000lbl.pdf